Welcome to our dedicated page for Cytomx Therapeutics news (Ticker: CTMX), a resource for investors and traders seeking the latest updates and insights on Cytomx Therapeutics stock.
CytomX Therapeutics (NASDAQ: CTMX) is a clinical-stage oncology company developing Probody antibody therapeutics for cancer treatment. This news feed tracks developments in CytomX's pipeline programs, clinical trial milestones, and corporate announcements as the company advances its tumor-targeting technology platform.
News coverage for CytomX typically centers on clinical trial updates from its Probody therapeutic candidates, including dose escalation data, patient enrollment milestones, and safety and efficacy readouts. For biotech investors, these trial updates often represent significant events that can inform understanding of the company's pipeline potential.
Beyond clinical developments, this feed includes partnership announcements with pharmaceutical collaborators who license Probody technology, financial results and business updates, conference presentations at oncology and investor meetings, and regulatory interactions. CytomX's strategic collaborations with larger pharmaceutical companies generate milestone payments and provide external validation of the Probody platform.
As a clinical-stage biopharmaceutical company focused on novel cancer therapeutics, CytomX's news flow reflects the typical milestones of drug development: trial initiations, interim data presentations, partnership expansions, and financing activities that fund ongoing research. Bookmark this page to follow CytomX's progress in bringing Probody technology from the laboratory to patients with cancer.
CytomX (NASDAQ: CTMX) provided a 2026 business update focused on clinical milestones for its PROBODY pipeline. Varsetatug masetecan (CX-2051) Phase 1 dose expansions (7.2, 8.6, 10 mg/kg Q3W) continue, with total Phase 1 enrollment projected at ~100 patients and a Phase 1 CRC expansion update expected in Q1 2026. The company aims to align with the FDA in 2026 on a potential registrational monotherapy study and plans a Varseta-M plus bevacizumab combination study to start in Q1 2026.
CX-801 (masked interferon-alpha-2b) is in Phase 1 for advanced melanoma; monotherapy reached dose level 4 and combination dose escalation with KEYTRUDA began in May 2025, with initial combo data expected by end of 2026. Management will present at JP Morgan on January 14, 2026.
CytomX Therapeutics (NASDAQ: CTMX) announced management will present at two investor conferences in December 2025: the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025 (fireside chat at 1:45 p.m. ET) in Coral Gables, FL, and the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025 (fireside chat at 1:00 p.m. ET) in New York, NY.
A live webcast will be available on the company’s Events and Presentations page at www.cytomx.com, and management will hold one-on-one meetings with registered conference attendees.
CytomX Therapeutics (Nasdaq: CTMX) said Sean McCarthy, D.Phil., chief executive officer and chairman, will take part in a fireside chat at the Jefferies Global Healthcare Conference in London on Thursday, November 20, 2025 at 9:00 a.m. GMT.
A live webcast will be available on the company’s Events and Presentations page at www.cytomx.com, and management will be available for one-on-one investor meetings for registered conference attendees.
CytomX Therapeutics (Nasdaq: CTMX) reported Q3 2025 results and a pipeline update on Nov 6, 2025. The company ended Q3 with $143.6 million in cash, cash equivalents and investments and expects runway to Q2 2027. Q3 revenue was $6.0 million versus $33.4 million a year earlier, driven by completion of Bristol Myers Squibb performance obligations and reduced Moderna activity. Operating expense for the quarter was $21.7 million and R&D was $15.3 million.
Pipeline highlights: CX-2051 Phase 1 expansion is ongoing, with projected enrollment of ~100 patients by a planned Phase 1 data update in Q1 2026; a CX-2051 Phase 1b combination with bevacizumab is expected to start in Q1 2026. CX-801 monotherapy biomarker data will be presented at SITC 2025 and supports ongoing combination dosing with KEYTRUDA; combo escalation began in May 2025.
CytomX Therapeutics (Nasdaq: CTMX) will present initial Phase 1 translational biomarker data for CX-801 (PROBODY interferon alpha-2b) at SITC 2025 (Nov 7–9).
Data demonstrate tumor-selective activation of interferon signaling and induction of immune cell populations and interferon-stimulated genes (including PD-1 and PD-L1) in paired tumor biopsies, and are reported as generally well tolerated in patients with metastatic melanoma refractory to prior checkpoint inhibitors. CytomX says these findings support the ongoing Phase 1 combination study of CX-801 with KEYTRUDA, with combination clinical data expected in 2026.
Poster: “Pharmacodynamic Activity of CX-801…” (Abstract 606) on Nov 8, 2025, 5:10–6:35 PM ET. Additional preclinical poster for CX-908 (Abstract 961) on Nov 7, 2025.
CytomX Therapeutics (Nasdaq: CTMX) will report its third quarter 2025 financial results on Thursday, November 6, 2025, after the close of U.S. markets.
The company will host a conference call and live webcast on November 6, 2025 at 5:00 p.m. ET / 2:00 p.m. PT. Participants can access the live webcast via the company’s Events and Presentations page and are advised to register at least 10 minutes before the call. An archived replay of the webcast will be available on the company website.
CytomX Therapeutics (Nasdaq: CTMX) on October 20, 2025 appointed Rachael Lester as Senior Vice President, Chief Business Officer to lead strategy and business development.
The company highlighted Lester’s two decades of experience in corporate strategy, partnerships and capital formation, citing prior roles as chief business officer at Replicate Bioscience, SVP of business development at Harpoon Therapeutics (acquired by Merck), and senior roles at Bruin Biometrics and Onyx Pharmaceuticals. Management said Lester will drive partnering and expand the PROBODY® platform while supporting lead clinical assets CX-2051 and CX-801 aimed at colorectal cancer and melanoma.
CytomX Therapeutics (NASDAQ: CTMX), a leader in masked, conditionally activated biologics, has announced its participation in three major investor conferences this September in New York.
The company will present at the Cantor Global Healthcare Conference (September 4), the H.C. Wainwright Global Investment Conference (September 9), and the Morgan Stanley Global Healthcare Conference (September 10). All presentations will be available via webcast on the company's website, and management will be available for one-on-one meetings with registered conference attendees.
CytomX Therapeutics (NASDAQ:CTMX) provided an update on its Phase 1 study of CX-2051 for colorectal cancer treatment. The CTMX-2051-101 study has successfully enrolled 73 patients across three dose expansion cohorts (7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg Q3W), with approximately 20 patients per dose level.
The company reported a single Grade 5 treatment-related adverse event involving acute kidney injury in a patient with a complex medical history. Following this event, reported to the FDA on July 18, 2025, the Safety Review Committee supported continued study execution. CytomX remains on track to provide a Phase 1 data update in Q1 2026.
CytomX Therapeutics (Nasdaq: CTMX) reported Q2 2025 financial results and significant clinical progress. The company announced positive interim data from Phase 1 study of CX-2051, their first-in-class EpCAM Antibody Drug Conjugate for advanced colorectal cancer, with Phase 2 study initiation planned for 1H 2026. CytomX also initiated combination dose escalation of CX-801 with KEYTRUDA® for advanced melanoma.
Financially, CytomX completed a $100 million common stock offering and ended Q2 2025 with $158.1 million in cash. Revenue was $18.7 million, down from $25.1 million year-over-year. Operating expenses decreased to $19.9 million from $33.6 million in Q2 2024. The company expects its cash runway to extend to Q2 2027.
FAQ
What is the current stock price of Cytomx Therapeutics (CTMX)?
What is the market cap of Cytomx Therapeutics (CTMX)?
